More than a year after Pfizer and venture capital company Flagship Pioneering struck a partnership investing in 10 life sciences programs, the two unveiled a collaboration with Quotient Therapeutics.
Pfizer (NYSE:PFE) reported that its BRAFTOVI combination therapy produced significant progression free survival benefits in ...
Pfizer (NYSE:PFE) reported positive topline results from its pivotal BREAKWATER trial. The study evaluated a BRAFTOVI based combination in previously untreated metastatic colorectal cancer with a BRAF ...
Pfizer reported positive Phase 2b results for its monthly GLP-1 obesity drug candidate PF-3944, with plans to run more than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results